CAR-T Cell Safety Switch via Suicide Gene and FOXP3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies (ACT) face challenges with serious adverse events such as cytokine storms and chronic toxicities, necessitating a safety mechanism for selective deletion of engineered immune cells.
Innovation Solution
Development of nucleic acid molecules and constructs that encode a chimeric antigen receptor (CAR), a safety switch polypeptide with a suicide moiety, and FOXP3, allowing for co-expression in immune cells to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If engineered immune cells are administered to improve therapeutic efficacy, then treatment effectiveness is improved, but serious adverse events such as cytokine storms and chronic toxicities occur
Solution Approach 1:
The patent applies preliminary anti-action by incorporating a suicide gene (HSV-TK) into the engineered T cells before administration. This suicide gene enables the cells to be selectively eliminated by ganciclovir if they cause adverse events. The safety mechanism is prepared in advance, allowing immediate termination of problematic cells without waiting for harm to occur, thus preventing cytokine storms and chronic toxicities while maintaining therapeutic efficacy.
2Productivity
If effector T cells are redirected to target tumor antigens, then anti-tumor activity is improved, but off-target toxicity occurs due to unexpected antigen expression on normal tissues
Solution Approach 1:
The patent applies preliminary anti-action by equipping CAR-T cells with a suicide gene (HSV-TK) that enables selective elimination by ganciclovir. If off-target toxicity occurs due to unexpected antigen expression on normal tissues, the suicide gene allows immediate termination of the engineered cells. This safety mechanism prevents further harm while the anti-tumor activity is maintained during the therapeutic period.
3Adaptability or versatility
If T cells are engineered to express heterologous receptors for targeted immunity, then specificity of immune response is improved, but safety control becomes more difficult
Solution Approach 1:
The patent applies preliminary anti-action by incorporating a suicide gene (HSV-TK) into CAR-T cells engineered with heterologous receptors. The suicide gene provides a built-in safety control mechanism that can be activated by ganciclovir administration. This allows easy safety control despite the high specificity of the engineered cells, as the suicide gene enables rapid termination of the therapeutic cells if safety issues arise.
4Adaptability or versatility
If multiple components are encoded in separate nucleic acid molecules, then flexibility of design is improved, but complexity of delivery and co-expression is increased
Solution Approach 1:
The patent applies merging by combining multiple nucleic acid components (CAR gene, suicide gene HSV-TK, and foXP3 gene) into a single nucleic acid molecule or vector. This single integrated construct ensures co-expression of all necessary components in the engineered T cells, simplifying the delivery process while maintaining design flexibility. The merged construct eliminates the need for multiple separate transfections or deliveries, reducing complexity while preserving the ability to design and optimize each component.
Data Source
AI summary
Provided herein is a nucleic acid molecule comprising 5′ to 3′ a first nucleotide sequence encoding a safety switch polypeptide comprising a suicide moiety; a second nucleotide sequence encoding FOXP3; and a third nucleotide sequence encoding a chimeric antigen receptor (CAR); particularly wherein said first, second, and third nucleotide sequences are separated by nucleotide sequences encoding self-cleavage sequences. Also provided are constructs, vectors and cells comprising the nucleic acid molecule, and methods and uses for expressing the encoded polypeptides in cells, particularly in immune cells useful in adoptive cell therapy (ACT).